Kamada was granted new (in addition to congenital emphysema and CF) Orphan drug designation by the FDA, for its inhaled AAT for the treatment of Bronchiectasis (currently undergoing Phase II clinical trials).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.